FDA's Halyna Breslawec, PhD
This article was originally published in The Gray Sheet
Executive SummaryIs resigning as associate director of the device center's office of device evaluation effective June 18. Breslawec is leaving the agency to spend more time with her family. A 14-year FDA veteran, Breslawec joined ODE as director of the investigational device exemption staff in 1984 and was promoted to director of ODE's division of gastroenterology, urology and general use devices in 1987. Breslawec was named associate director of ODE in 1990.
You may also be interested in...ï»¿
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committeeâ€™s approach to penalize companies for raising WAC list prices is not a â€˜price control,â€™ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.